University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

D. Montgomery Bissell, M.D.

Chief of Gastroenterology

Dr. D. Montgomery Bissell is chief of Gastroenterology at UCSF Medical Center and director of the National Institutes of Health (NIH)-supported Liver Center, a consortium of 40 independently funded researchers who study the liver and its diseases. Bissell has a career-long interest in liver disease, dating to when he conducted a project on hepatocellular carcinoma in East Africa as a Harvard medical student. He then turned his attention to defining the cellular responses and molecular regulation of the scarring process known as fibrosis and cirrhosis. The latter is the most important consequence of many chronic liver diseases including inborn errors of metabolism, viral hepatitis, autoimmune states, alcohol abuse and others. It also is the setting for most cases of liver cancer.

Since 1981, Bissell has led the Rice-Liver Center Laboratory at San Francisco General Hospital, known internationally for basic research on fibrosis and defining new therapies to block fibrosis progression in patients. He is a member of several professional organizations including the American Society for Clinical Investigation and the Association of American Physicians and has served on numerous review panels for NIH, the Veterans Administration and other groups.


Liver Disease and Liver Transplant
350 Parnassus Ave., Suite 300
San Francisco, CA 94143
Phone: (415) 353-2318
Fax: (415) 353-2407

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

More about D. Montgomery Bissell

Additional Languages



Harvard University School of Medicine 1967


Boston City Hospital, General Medicine 1970


UCSF Medical Center, GI Research/Liver 1973

Selected Research and Publications

  1. Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, Phillips JD, Naik H, Peter I, Baillargeon G, Bossi K, Gandolfo L, Light C, Bishop D, Desnick RJ. Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias Consortium. Am J Med. 2014 Dec; 127(12):1233-41.
  2. Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Liu L, Desnick RJ. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med. 2013; 19:26-35.
  3. Bissell DM. Therapy for hepatic fibrosis: revisiting the preclinical models. Clin Res Hepatol Gastroenterol. 2011 Sep; 35(8-9):521-5.
  4. Bissell DM. Inflammation and hepatic fibrosis. Semin Liver Dis. 2010 Aug; 30(3):211-4.
  5. Bissell DM. Of mentors, mentoring, and extracellular matrix. Hepatology. 2009 Nov; 50(5):1330-8.
  6. Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM. Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. BMC Med Genomics. 2009; 2:51.
  7. Okayama T, Kikuchi S, Ochiai T, Ikoma H, Kubota T, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Sonoyama T, Kokuba Y, Doi Y, Tsukita S, Bissell DM, Otsuji E. Attenuated response to liver injury in moesin-deficient mice: impaired stellate cell migration and decreased fibrosis. Biochim Biophys Acta. 2008 Sep; 1782(9):542-8.
  8. Wang B, Dolinski BM, Kikuchi N, Leone DR, Peters MG, Weinreb PH, Violette SM, Bissell DM. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology. 2007 Nov; 46(5):1404-12.
  9. Chang ML, Chen JC, Yeh CT, Sheen IS, Tai DI, Chang MY, Chiu CT, Lin DY, Bissell DM. Topological and evolutional relationships between HCV core protein and hepatic lipid vesicles: studies in vitro and in conditionally transgenic mice. World J Gastroenterol. 2007 Jul 7; 13(25):3472-7.
  10. Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology. 2007 Jan; 45(1):242-9.
  11. Schenker S, Bissell DM, Blei AT. Hepatology over the years. Hepatology. 2006 Feb; 43(2 Suppl 1):S6-S12.
  12. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006 Feb; 43(2 Suppl 1):S113-20.
  13. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baetscher M, Baestcher M, Wang B, Bissell DM, Burkly LC. TWEAK induces liver progenitor cell proliferation. J Clin Invest. 2005 Sep; 115(9):2330-40.
  14. Kikuchi S, Griffin CT, Wang SS, Bissell DM. Role of CD44 in epithelial wound repair: migration of rat hepatic stellate cells utilizes hyaluronic acid and CD44v6. J Biol Chem. 2005 Apr 15; 280(15):15398-404.
  15. Chang ML, Chen JC, Alonso CR, Kornblihtt AR, Bissell DM. Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver. Proc Natl Acad Sci U S A. 2004 Dec 28; 101(52):18093-8.
  16. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology. 2004 Dec; 127(6):1847-9.
  17. Bissell D. The origin of hepatic myofibroblasts. Mak KM, Leo MA, Lieber CS. Alcoholic liver injury in baboons: transformation of lipocytes to transitional cells [Gastroenterology 1984;87:188-200]. J Hepatol. 2002 Sep; 37(3):298.
  18. Alonso CR, George J, Pesce CG, Bissell DM, Kornblihtt AR. Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes. Biochem Biophys Res Commun. 2002 Aug 2; 295(5):1077-84.
  19. Bissell DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med. 2001 Dec 31; 33(4):179-90.
  20. Bissell DM. International hepatology. Hepatology. 2001 Dec; 34(6):1252-3.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.